Advanced Biomed (ADVB) revenue and earnings history
Advanced Biomed reported revenue of $128K for fiscal 2026 (year ended Jun 30, 2026), and net income of $6.68M.
Revenue and net income, 3 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Jun 30, 2026 | $128K | −$6.23M | $6.68M | −$1.95M | — | — | $1.73M | — | — | $386K | — | 10-K |
| 2025ended Jun 30, 2025 | — |
The latest quarter, insider trades and fund moves: Advanced Biomed (ADVB) on OQRO.
Common questions
What was Advanced Biomed's revenue in fiscal 2026?
$128K for the year ended Jun 30, 2026, as reported in its 10-K filed Oct 13, 2026.
Has Advanced Biomed been profitable?
It reported a net loss in 2 of the years shown (2024, 2025). The highest net income was $6.68M in fiscal 2026.
Why is earnings per share not in this table?
Each year's figure here comes from the newest annual report that states it. After a stock split, earlier reports and later reports state per-share figures on different share counts, so a column of EPS would mix the two. Net income is not affected by splits.
Where these figures come from
The SEC’s companyfacts data: every figure Advanced Biomed tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.